

كلية الطب قسم التخدير والرعاية المركزة

مقارنة عقار الريميفنتانيل مع عقار الفنتانيل في تسكين الألم أثناء الولادة عن طريق تحكم المريض

رسالة توطئة للحصول على درجه الدكتوراة في التخدير مقدمة من

الطبيب / محمد احمد عبد القادر احمد بكالوريوس الطب والجراحة ماجستير التخدير تحت اشر اف

أ.د./ محمود شريف مصطفى أستاذ التخدير والرعاية المركزة - كلية الطب- جامعة عين شمس أد./ نهال جمال الدين نوح أستاذ التخدير والرعاية المركزة كلية الطب- جامعة عين شمس أد./ جمال الدين محمد عليوه أستاذ التخدير والرعاية المركزة كلية الطب- جامعة عين شمس كلية الطب- جامعة عين شمس

كلية الطب جامعة عين شمس 2011



Faculty of Medicine Anesthesiology department

Remifentanil Versus Fentanyl for Patient Controlled Analgesia in labour

Thesis

Submitted For Partial Fulfillment of M.D Degree In Anesthesia

By

Mohamed Ahmed Abdel kader Ahmed M.B.B.Ch, M.Sc (Anesthesia)

Under the supervision of

Prof. Dr. Mahmoud Sharif Moustafa
Professor of Anesthesiology and Intensive Care
Faculty of Medicine, Ain Shams University

Prof. Dr. Nehal Gamal El Din Nooh

Professor of Anesthesiology and Intensive Care
Faculty of Medicine, Ain Shams University

Prof. Dr. Gamal Eldin Mohammad Elewa Professor of Anesthesiology and Intensive Care Faculty of Medicine, Ain Shams University

> Faculty of Medicine Ain Shams University 2011



INTRODUCTION

Many women regard labour as the most extreme painful experience in their lives. This experience forced upon them by their sex that means they must undergo such an experience in order to get children. But instead of offering comfort and support, many popular socio-cultural beliefs, and even religions reinforce the worst fears of these women with stories of pain and misery.

Of course, labour pain can result in failure of progression of labour which can cause maternal exhaustion and/or foetal distress. Also, the personal experience of extreme pain during labour or delivery is related to the occurrence of postnatal depression (Hiltunen et al., 2004 and Ferber et al., 2005).

So, there are very good reasons for effective management of labour pain, as the fact that some women may feel the necessity for labour analgesia (**Kannan** *et al.*, **2001**).

Luckily, there are variety of techniques which have been developed over the years to soften the pangs of childbirth; for example: psychoprophylaxis, transcutaneous electrical nerve stimulation (TENS), entonox, etc.

Many women derive considerable psychological benefit from antenatal preparations. Even so, not all women and births are the same, and for some women labour pains are unexpectedly worse than they can conceive or endure (**Keirse** *et al.*, **1989**).

In TENS, electrodes are applied to the back of the women, and electrical pulses stimulate sensory nerves, blocking the pain gating systems in the spinal cord. But regardless of how wonderful this sounds, this technique is insufficiently effective for many women(**Bundsen** *et al.*, **1981**).

Many women find that entonox is an unsatisfactory analgesic for established labour (Carstoniu et al., 1994), and some are unable to use it effectively because of induced nausea and vomiting. Nitrous oxide may pose a risk to personnel working in areas where it is used for long periods of time without adequate scavenging facilities (Ahlborg et al., 1996).

Although, IM meperidine is the most common method of providing labour analgesia (Rawal and Allvin, 1996). Yet, its effectiveness is limited (Ranta et al., 1994), and it is associated with many harmful fetal and neonatal effects (Kariniemi et al., 1981).

Epidural blockade is known to be effective and safe in labour pain treatment. There are, however, situations when it is contraindicated, for example infections or bleeding disorders. In many hospitals, anaesthesia services and epidural blockade are not available 24 hr a day. Also, it has been suggested that



epidural blockade in labour is associated with increased maternal intrapartum fever and neonatal sepsis requiring antibiotic treatment (**Lieberman** *et al.*, 1997) Therefore, alternatives for labour analgesia are needed.

Patient-controlled analgesia (PCA) techniques are not new to obstetrics: PCA is the standard delivery system for Entonox, Meperidine (Evans et al., 1976), butorphenol tartrate (Vogelsang and Hayes 1991), tramadol (Lewis et al., 1997), nalbuphine (Frank et al., 1987) and fentanyl (Roseag et al., 1992).

Remifentanil is a novel, ultra short-acting esterase metabolized synthetic opioid. It is a selective mu opioid agonist and has an ester linkage rendering it susceptible to rapid metabolism by non-specific blood and tissue esterases. (**Michelsen and Hug 1996**). It is an ideal drug for the intermittent painful contractions of labour (**Kan** *et al.*, **1998**).

These characteristics may make remifentanil a suit-able drug for use in a patient-controlled analgesia system (PCA), with or without a background infusion, for analgesia in labour where severe pain occurs at intervals and rapid recovery between contractions and after delivery is desirable (**Harbers** *et al.*, **2008**).



AIM OF THE WORK

The aim of the work was to compare remifentanil with fentanyl for intravenous (I.V.) patient controlled analgesia (PCA) in Labour and to evaluate its safety on the delivered babies.






Figure	Titles				
1	Stage 1: Dilation of the cervix				
2	Stage 2: Expulsion of the fetus				
3	Stage 3: Expulsion of the placenta	8			
4	A typical modern PCA pump	30			
5	Comparison of the context sensitive half times for alfentanil, sufentanil, fentanyl and remifentanil				
6	Comparison between fentanyl and remifentanil groups as regard maternal oxygen saturation during the study period.	76			
7	Comparison between fentanyl primigravida and remifentanil primigravida subgroups as regard maternal oxygen saturation during the study period.	77			
8	Comparison between fentanyl multigravida and remifentanil multigravida subgroups as regard maternal oxygen saturation during the study period.	77			
9	Comparison between fentanyl primigravida and fentanyl multigravida subgroups as regard maternal oxygen saturation during the study period.	78			

Figure	Titles	Page
10	Comparison between remifentanil primigravida and remifentanil multigravida subgroups as regard maternal oxygen saturation during the study period.	78
11	Comparison between fentanyl and remifentanil groups as regard sedation during the study period.	79
12	Comparison between fentanyl primigravida and remifentanil primigravida subgroups as regard sedation during the study period.	80
13	Comparison between fentanyl multigravida and remifentanil multigravida subgroups as regard sedation during the study period.	80
14	Comparison between fentanyl primigravida and fentanyl multigravida subgroups as regard sedation during the study period.	81
15	Comparison between remifentanil primigravida and remifentanil multigravida subgroups as regard sedation during the study period.	81
16	Comparison between fentanyl primigravida, remifentanil primigravida, fentanyl multigravida and remifentanil multigravida subgroups as regard nausea and vomiting during the study period.	82
17	Comparison between fentanyl primigravida, remifentanil primigravida, fentanyl multigravida and remifentanil multigravida subgroups as regard itching during the study period.	83



Figure	Titles				
18	Comparison between fentanyl and remifentanil groups as regard frequency of uterine contraction during the study period.	92			
19	Comparison between fentanyl primigravioda and remifentanil primigravioda as regard frequency of uterine contraction during the study period.	92			
20	Comparison between fentanyl multigravioda and remifentanil multigravioda as regard frequency of uterine contraction during the study period.	93			
21	Comparison between fentanyl primigravioda and fentanyl multigravioda as regard frequency of uterine contraction during the study period.	93			
22	Comparison between remifentanil primigravioda and remifentanil multigravioda as regard frequency of uterine contraction during the study period.	94			






Table	Titles	Page			
1	Pain severity and degree of discomfort according to stages of labour				
2	Comparison of the pharmacokinetics of remifentanil, alfentanil, fentanyl and sufentanil	38			
3	Parturients' demographic data and cervical dilatation before starting PCA in both fentanyl and remifentanil groups	53			
4	Parturients' demographic data and cervical dilatation before starting PCA in both fentanyl and remifentanil primigravida subgroups.	53			
5	Parturients' demographic data and cervical dilatation before starting PCA in both fentanyl and remifentanil multigravida subgroups.	54			
6	Parturients' demographic data and cervical dilatation before starting PCA in both fentanyl primigravida and multigravida subgroups.	55			
7	Parturients' demographic data and cervical dilatation before starting PCA in both remifentanil primigravida and multigravida subgroups.	55			
8	Comparison between fentanyl and remifentanil groups as regards systolic blood pressure during the study period	56			



9	Comparison between fentanyl and remifentanil primigravida subgroups as regards systolic blood pressure during the study period					
10	Comparison between fentanyl and remifentanil multigravida subgroups as regards systolic blood pressure during the study period					
11	Comparison between fentanyl primigravida and fentanyl multigravida subgroups as regards systolic blood pressure during the study period	59				
12	Comparison between remifentanil primi-gravida and remifentanil multigravida subgroups as regards systolic blood pressure during the study period.					
13	Comparison between fentanyl and remifentanil groups as regards diastolic blood pressure during the study period.	61				
14	Comparison between fentanyl and remifentanil primigravida subgroups as regards diastolic blood pressure during the study period.	62				
15	Comparison between fentanyl and remifentanil multigravida subgroups as regards diastolic blood pressure during the study period.	63				
16	Comparison between fentanyl primigravida and fentanyl multigravida subgroups as regards diastolic blood pressure during the study period.	64				
17	Comparison between remifentanil primigravida and remifentanil multigravida subgroups as regards diastolic blood pressure during the study period.	65				



18	Comparison between fentanyl and remifentanil groups as regards maternal heart rate during the study period.	66
19	Comparison between fentanyl and remifentanil primigravida subgroups as regards maternal heart rate during the study period.	67
20	Comparison between fentanyl and remifentanil multigravida subgroups as regards maternal heart rate during the study period.	68
21	Comparison between fentanyl primigravida and fentanyl multigravida subgroups as regards maternal heart rate during the study period.	69
22	Comparison between remifentanil primigravida and remifentanil multigravida subgroups as regards maternal heart rate during the study period.	70
23	Comparison between fentanyl and remifentanil groups as regards respiratory rate during the study period.	71
24	Comparison between fentanyl and remifentanil primigravida subgroups as regards respiratory rate during the study period.	72
25	Comparison between fentanyl and remifentanil multigravida subgroups as regards respiratory rate during the study period.	73
26	Comparison between fentanyl primigravida and fentanyl multigravida subgroups as regards respiratory rate during the study period.	74



27	Comparison between remifentanil primigravida and remifentanil multigravida subgroups as regards respiratory rate during the study period.					
28	Number of cases who had chest tightness.					
29	comparison between fentanyl and remifentanil groups as regard FHR during the study period.	86				
30	Comparison between fentanyl primigravida, remifentanil primigravida, fentanyl multigravida and remifentanil multigravida subgroups as regard APGAR score at one minute during the study period.	87				
31	Comparison between studied groups as regard APGAR score at five minutes during the study period.	87				
32	The delivery time (min) (first, second and third stages) for fentanyl and remifentanil groups.	88				
33	The delivery time (min) (first, second and third stages) for fentanyl and remifentanil primigravida groups	88				
34	The delivery time (min) (first, second and third stages) for fentanyl and remifentanil multigravida groups	89				
35	The delivery time (min) (first, second and third stages) for fentanyl primigravida and fentanyl multigravida subgroups	89				
36	The delivery time (min) (first, second and third stages) for remifentanil primigravida and remifentanil multigravida subgroups	90				



37	The difference between the two main groups as regard the equipotent doses of drug given	90
38	The number of cases had episiotomy in all subgroups.	91
39	The overall satisfaction score for studied groups	94
40	The overall satisfaction for all subgroups	95





		Titles	Page
INTRODUCTION			1
AIM OF THE WORK			4
REVIEW	OF	F LITERATURE	5
I- I	Lab	our pain	5
•	•	Neural pathway of labour pain	5
•	•	Physiology of labour pain	6
•	•	Factors affecting labour pain	8
•	•	Stress response of labour pain	10
II- I	Reli	ef of labour pain	12
•	•	History of labour pain relief	12
•	•	Methods of pain relief	13
•	•	Opioids for labour pain relief	17
III- I	[.V.	Patient controlled analgesia (PCA)	30
IV- I	Fen	tanyl and remifentanil in labour	33
A	4.	Fentanyl as I.V.PCA in labour	33
F	3.	Remifentanil as I.V.PCA in labour	37
PATIENT	Γ S A	AND METHODS	46
RESULTS	S	•••••	52
DISCUSSION			96
CONCLUSION			107
SUMMARY			108
REFERENCES			111
ARABIC	SU	MMARY	